|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Mesalazine preparations for the treatment of ulcerative colitis: Are all created equal?显示文摘Oral mesalazine(also known as mesalamine) is a 5-aminosalicylic acid compound used in the treatment of mild to moderate ulcerative colitis, with high rates of efficacy in induction and maintenance of remission.The therapeutic effect of mesalazine occurs topically at the site of diseased colonic mucosa. A myriad of oral mesalazine preparations have been formulated with various drug delivery methods to minimize systemic absorption and maximise drug availability at the inflamed colonic epithelium. It remains unclear whether different oral mesalazine formulations are bioequivalent. This review aims to evaluate the differences between mesalazine formulations based on the currently available literature and explore factors which may influence the selection of one agent above another. | Bei Ye Daniel R van Langenberg | 2015 | World Journal of Gastrointestinal Pharmacology and Therapeutics2015，6，4： | 14 |
| 2 | Inflammatory bowel disease serology in Asia and the West显示文摘AIM:To study serological antibodies in Caucasians and Asians,in health and inflammatory bowel disease(IBD),in Australia and Hong Kong(HK).METHODS:Anti-glycan antibodies[anti-chitobioside(ACCA),anti-laminaribioside(ALCA)],and anti-mannobioside(AMCA),anti-Saccharomyces cervisiae(gASCA);and atypical perinuclear anti-neutrophil cytoplasmic antibody(pANCA)were tested in IBD patients,their unaffected relatives,and healthy controls in Australia and HK(China).Antibody status(positive or negative)and titre was compared between subjects of different geography,ethnicity and disease state.RESULTS:Ninety subjects were evaluated:21 Crohn’s disease(CD),32 ulcerative colitis(UC),29 healthy controls,and 8 IBD patient relatives.Forty eight subjects were Australian(29 Caucasian and 19 ethnic Han Chinese)and 42 were from HK(all Han Chinese).Caucasian CD patients had a significantly higher antibody prevalence of gASCA(67%vs 3%,P<0.001),ALCA(44%vs 6%,P=0.005),and AMCA(67%vs 15%,P=0.002),whereas HK CD patients had a higher prevalence of only AMCA(58%vs 25%,P=0.035),when compared with UC and healthy subjects in both countries.Caucasian CD had significantly higher gASCA prevalence(67%vs 0%,P<0.001)and titre(median59 vs 9,P=0.002)than HK CD patients.Prevalence and titres of ALCA,ACCA and AMCA did not differ between CD in the two countries.Presence of at least one antibody was higher in Caucasian than HK CD patients(100%vs 58%,P=0.045).pANCA did not differ between countries or ethnicity.CONCLUSION:Serologic CD responses differ between HK Asian and Australian Caucasian patients.Different genetic,environmental or disease pathogenic factors may account for these differences. | Lani Prideaux Michael A Kamm Peter De Cruz Daniel R van Langenberg Siew C Ng Iris Dotan | 2013 | World Journal of Gastroenterology2013，19，37： | 10 |
| 3 | Satisfaction with patient-doctor relationships in inflammatory bowel diseases:Examining patient-initiated change of specialist显示文摘AIM:To assess the reasons for,and factors associated with,patient-initiated changes in treating specialist in inflammatory bowel diseases(IBD).METHODS:Prospectively identified IBD patients(n = 256) with ≥ 1 encounter at a metropolitan hospital were surveyed,including whether they had changed treating specialist and why.Negative reasons included loss of confidence,disagreement,and/or personality clash with the specialist.RESULTS:Of 162 respondents,70(43%) had ever changed specialists;30/70(43%) for negative reasons,52/70(74%) in the preceding year.Patients with negative reasons for changing(n = 30) were younger(median,35.2 years vs 45.3 years),had higher IBD knowledge(median,5.0 years vs 4.0 years),yet had lower medication adherence and satisfaction scores(median,19.0 years vs 22.0 years,14.0 years vs 16.0 years respectively,Mann-Whitney tests,all P < 0.05),compared to all other responders(n = 132).Patients with a recent change(for any reason) were more likely to have Crohn's disease,currently active disease,previous bowel resection and recent hospitalization [OR 2.6,95% CI(1.3-5.4),2.2(1.0-4.7),5.56(1.92-16.67),2.0(1.3-3.0),eachP < 0.05].CONCLUSION:Changing specialist appears associated with patient-related(age,nonadherence) and contemporaneous disease-related factors(recent relapse) which,where modifiable,may enhance patient-doctor relationships and therefore quality of care. | Daniel R van Langenberg Jane M Andrews | 2012 | World Journal of Gastroenterology2012，18，18： | 5 |
| 4 | Time to clinical response and remission for therapeutics in inflammatory bowel diseases: what should the clinician expect, what should patients be told?显示文摘An awareness of the expected time for therapies to induce symptomatic improvement and remission is necessary for determining the timing of follow-up, disease(re)assessment, and the duration to persist with therapies, yet this is seldom reported as an outcome in clinical trials. In this review, we explore the time to clinical response and remission of current therapies for inflammatory bowel disease(IBD) as well as medication, patient and disease related factors that may influence the time to clinical response. It appears that the time to therapeutic response varies depending on the indication for therapy(Crohn's disease or ulcerative colitis). Agents with the most rapid time to clinical response included corticosteroids, calcineurin inhibitors, exclusive enteral nutrition, aminosalicylates and anti-tumor necrosis factor therapy which will work in most patients within the first 2 mo. Vedolizumab,methotrexate and thiopurines had a longer time to clinical response and can take several months to achieve maximal efficacy. Factors affecting the time to clinical response of therapies included use of concomitant therapy, disease duration, smoking status, disease phenotype and advanced age. There appears to be marked variation in time to clinical response for therapies used in IBD which is further influenced by disease and patient related factors. Understanding the expected time to therapeutic response is integral to inform further decision making, maintain a patientcentered approach and ensure treatment is given an appropriate timeframe to achieve maximal benefit prior to cessation. | Abhinav Vasudevan Peter R Gibson Daniel R van Langenberg | 2017 | World Journal of Gastroenterology2017，23，35： | 4 |
| 5 | Deep learning vs conventional learning algorithms for clinical prediction in Crohn's disease: A proof-of-concept study显示文摘BACKGROUND Traditional methods of developing predictive models in inflammatory bowel diseases(IBD)rely on using statistical regression approaches to deriving clinical scores such as the Crohn's disease(CD)activity index.However,traditional approaches are unable to take advantage of more complex data structures such as repeated measurements.Deep learning methods have the potential ability to automatically find and learn complex,hidden relationships between predictive markers and outcomes,but their application to clinical prediction in CD and IBD has not been explored previously.AIM To determine and compare the utility of deep learning with conventional algorithms in predicting response to anti-tumor necrosis factor(anti-TNF)therapy in CD.METHODS This was a retrospective single-center cohort study of all CD patients who commenced anti-TNF therapy(either adalimumab or infliximab)from January 1,2010 to December 31,2015.Remission was defined as a C-reactive protein(CRP)<5 mg/L at 12 mo after anti-TNF commencement.Three supervised learning algorithms were compared:(1)A conventional statistical learning algorithm using multivariable logistic regression on baseline data only;(2)A deep learning algorithm using a feed-forward artificial neural network on baseline data only;and(3)A deep learning algorithm using a recurrent neural network on repeated data.Predictive performance was assessed using area under the receiver operator characteristic curve(AUC)after 10×repeated 5-fold cross-validation.RESULTS A total of 146 patients were included(median age 36 years,48%male).Concomitant therapy at anti-TNF commencement included thiopurines(68%),methotrexate(18%),corticosteroids(44%)and aminosalicylates(33%).After 12 mo,64%had CRP<5 mg/L.The conventional learning algorithm selected the following baseline variables for the predictive model:Complex disease behavior,albumin,monocytes,lymphocytes,mean corpuscular hemoglobin concentration and gamma-glutamyl transferase,and had a cross-validated AUC of 0.659,95%confidence interval(CI):0.562-0.756.A feed-forward artificial neural network using only baseline data demonstrated an AUC of 0.710(95%CI:0.622-0.799;P=0.25 vs conventional).A recurrent neural network using repeated biomarker measurements demonstrated significantly higher AUC compared to the conventional algorithm(0.754,95%CI:0.674-0.834;P=0.036).CONCLUSION Deep learning methods are feasible and have the potential for stronger predictive performance compared to conventional model building methods when applied to predicting remission after anti-TNF therapy in CD. | Danny Con Daniel R van Langenberg Abhinav Vasudevan | 2021 | World Journal of Gastroenterology2021，27，38： | 2 |
| 6 | The fellow eye in NAION: report from the ischemic optic neuropathy decompression trial follow-up study显示文摘 | Newman NJ Scherer R Langenberg P | 2002 | Am J Ophthalmol2002，134，3： | 1 |
| 7 | Renal blood flow in sepsis 显示文摘 | Langenberg C Bellomo R May C | 2005 | Crit Care2005，9，4： | 1 |
| 8 | Renal blood flow in sepsis显示文摘 | Langenberg C Bellomo R May C | 2005 | Crit Care2005，9，4： | 1 |
| 9 | Birthweight, childhood growth, and blood pressure at 43 yeat in a British birth cohort显示文摘 | Hardy R Wadsworlh ME Langenberg C | 2004 | Int J Epidemiol2004，33，： | 1 |
| 10 | Cardiovascular risk at age 53 years in relation to the menopause transition and use of hormone replacement therapy : a prospective British birth cohort study 显示文摘 | Kuh D Langenberg C Hardy R | 2005 | BJOG2005，112，4： | 1 |
| 11 | Polymer-based paclitaxel-eluting stents are superior to nonpolymer-based paclitaxel-eluting stents in the treatment of de novo coronary lesions显示文摘 | Iofina E Langenberg R Blindt R | 2006 | The American Journal of Cardiology2006，，98： | 1 |
| 12 | The fellow eye in NAION : report from the isehemic optic neuropathy decompression trial follow-up study 显示文摘 | Newman NJ Scherer R Langenberg P | 2002 | Am J Ophthalmol2002，134，3： | 1 |
| 13 | Numerical modeling of elastic wave propagation and scattering with EFIT - elastodynamic finite integration technique显示文摘 | Fellinger P Marklein R Langenberg K J | 1995 | Wave Motion1995，21，1： | 1 |
| 14 | Application of modeling techniques for ultrasonic austenitic weld inspection显示文摘 | Langenberg K J Hannemann R Kaczorowski T | 2000 | NDT & E International2000，33，10： | 1 |
| 15 | Interior proximal methods for quasiconvex optimization显示文摘 | Langenberg N Tichatschke R | 2012 | Joumal of Global Optimization2012，52，3： | 1 |
| 16 | Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials Chiron HSV Vaccine Study Group显示文摘 | Corey L Langenberg AG Ashley R | | 0，，： | 1 |
| 17 | Cardiovascular risk at age 53 years in relation to the menopause transition and use of hormone replacement therapy:a prospective British birth cohort study显示文摘 | Kuh D Langenberg C Hardy R | 2005 | B JOG2005，112，4： | 1 |
| 18 | Grain refinement of steel ingots by solidification in a moving electromagnetic field显示文摘 | LANGENBERG F C PESTEL G HONEYCUTT C R | 1961 | Trans Metall Soc AIME1961，221，： | 1 |
| 19 | Renal blood flow in sepsis 显示文摘 | Langenberg C Bellomo R May C | 2005 | Crit Care2005，9，4： | 1 |
| 20 | Influence of height,leg and trunk length on pulse pressure, systolic and diastolic blood pres- sure显示文摘 | Langenberg C Hardy R Kuh D | 2003 | J Hypertens2003，21，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员